Rosiglitazone inhibits K v4.3 potassium channels by open-channel block and acceleration of closed-state inactivation

British Journal of Pharmacology

Volumn 163, Issue 3, 2011, Pages 510-520

  Jeong, I ^a   Choi, B H ^b   Hahn, S J ^a  

^a The Catholic University of Korea   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

closed state inactivation; K v4.3; open channel block; PPAR ; rosiglitazone; type 2 diabetes

Indexed keywords

DELAYED RECTIFIER POTASSIUM CHANNEL; POTASSIUM CHANNEL KV4.3; ROSIGLITAZONE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; POTASSIUM CHANNEL KV1.3; SHAL POTASSIUM CHANNEL;

ANIMAL CELL; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG EFFICACY; DRUG POTENCY; ELECTROPHYSIOLOGY; HYPERPOLARIZATION; IC 50; KINETICS; MEMBRANE DEPOLARIZATION; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; ARTICLE; CHANNEL GATING; CHO CELL; CRICETULUS; DOSE RESPONSE; DRUG ANTAGONISM; HAMSTER; TIME;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; ION CHANNEL GATING; KV1.3 POTASSIUM CHANNEL; PATCH-CLAMP TECHNIQUES; SHAL POTASSIUM CHANNELS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 79955911273     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01210.x     Document Type: Review

References (37)

1. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, et al,. (2006). Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 319: 323-331.
2. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, et al,. (2007). Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn Schmiedebergs Arch Pharmacol 374: 305-309. (Pubitemid 46091586)
3. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
4. Bean BP, Cohen CJ, Tsien RW, (1983). Lidocaine block of cardiac sodium channels. J Gen Physiol 81: 613-642. (Pubitemid 13062306)
5. Beck EJ, Covarrubias M, (2001). Kv4 channels exhibit modulation of closed-state inactivation in inside-out patches. Biophys J 81: 867-883. (Pubitemid 32721458)
6. Butterworth JFT, Strichartz GR, (1990). Molecular mechanisms of local anesthesia: a review. Anesthesiology 72: 711-734. (Pubitemid 20114720)
7. + current but not the inward rectifier in rat ventricular myocytes. J Pharmacol Exp Ther 255: 1038-1046.
8. Courtney KR, (1975). Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther 195: 225-236.
9. + channel behaves like an open-channel blocker. Neuron 7: 743-753.
10. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res 79: 659-668. (Pubitemid 26317813)
11. Fujiwara T, Horikoshi H, (2000). Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 67: 2405-2416.
12. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, et al,. (1996). Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277: 1630-1641. (Pubitemid 27167181)
13. Janse MJ, Wit AL, (1989). Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 69: 1049-1169. (Pubitemid 19255835)
14. Jeck C, Pinto J, Boyden P, (1995). Transient outward currents in subendocardial Purkinje myocytes surviving in the infarcted heart. Circulation 92: 465-473.
15. + channel inactivation mediated by the concerted action of the cytoplasmic N- and C-terminal domains. Biophys J 72: 163-174. (Pubitemid 27043426)
16. Kaab S, Dixon J, Duc J, Ashen D, Nabauer M, Beuckelmann DJ, et al,. (1998). Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 98: 1383-1393. (Pubitemid 28462798)
17. Kass RS, Cabo C, (2000). Channel structure and drug-induced cardiac arrhythmias. Proc Natl Acad Sci USA 97: 11683-11684.
18. + channels, Kv1.3 and Kv3.1, by sibutramine. J Pharmacol Exp Ther 321: 753-762.
19. Knock GA, Mishra SK, Aaronson PI, (1999). Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 368: 103-109. (Pubitemid 29106420)
20. Korantzopoulos P, Kokkoris S, Kountouris E, Protopsaltis I, Siogas K, Melidonis A, (2008). Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. Int J Cardiol 125: e51-e53. (Pubitemid 351418030)
21. Lacerda AE, Roy ML, Lewis EW, Rampe D, (1997). Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol 52: 314-322. (Pubitemid 27349624)
22. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA, (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956.
23. Lehmann-Horn F, Rudel R, (1995). Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol 8: 402-410.
24. ATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia 51: 675-685.
25. + current in rat aorta myocytes. Eur J Pharmacol 386: 121-125. (Pubitemid 30009631)
26. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. (Pubitemid 46919772)
27. + channel alpha-subunit, Kv4.3 in the rat. FEBS Lett 420: 47-53. (Pubitemid 28037198)
28. 2+ currents by PPAR-γ agonists in cultured hippocampal neurons. J Neurochem 109: 1800-1811.
29. Patel SP, Parai R, Campbell DL, (2004). Regulation of Kv4.3 voltage-dependent gating kinetics by KChIP2 isoforms. J Physiol 557: 19-41. (Pubitemid 38771635)
30. Singh S, Loke YK, Furberg CD, (2007a). Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195. (Pubitemid 47403105)
31. Singh S, Loke YK, Furberg CD, (2007b). Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30: 2148-2153. (Pubitemid 47219440)
32. + channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther 269: 66-74. (Pubitemid 24143236)
33. Snyders DJ, Yeola SW, (1995). Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ Res 77: 575-583.
34. Snyders J, Knoth KM, Roberds SL, Tamkun MM, (1992). Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol 41: 322-330.
35. Wagstaff AJ, Goa KL, (2002). Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62: 1805-1837. (Pubitemid 34948176)
36. Wang Z, Fermini B, Nattel S, (1995). Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 272: 184-196.
37. Wulff H, Castle NA, Pardo LA, (2009). Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8: 982-1001.